The Ministry of Industry and Trade announced an increase in essential drugs production in the Russian Federation


Russian pharmaceutical companies are increasing the production of essential drugs, in particular antibiotics, antipyretics and cancer drugs, the press service of the Ministry of Industry and Trade of the Russian Federation reported.

“Over the past few years, Russian pharmaceutical manufacturers have been using all their capacities in order to achieve the most important goal – to provide Russians with the most necessary medicines,” TASS quotes the message.

According to the Ministry, amoxicillin based antibiotics in injection and tablet form are produced by several Russian manufacturers. For example, Biokhimik, a production site of Promomed group, intends to produce more than 1.5 million vials of Amclav and over 80 million tablets of Amoxicillin in 2023. The supplies of ibuprofen suppositories have stabilized. Pharmasyntez has produced and already shipped a six-month supply of pediatric ibuprofen.

Pharmasynthez also shipped a six-month supply of Zifluсort, a hormonal drug used for chronic adrenal insufficiency. At its site in Tyumen, the company develops new dosage forms of hormonal drugs and introduces them into production.

As for cancer drugs, Ozon pharmaceutical company plans to introduce into civil circulation more than 200,000 packages of Tamoxifen, a breast cancer therapy, in two dosage forms, by the end of January. The Ministry of Industry and Trade stressed that the entire volume will be immediately shipped to distributors.

Grotex (its products are branded Solopharmbrand) produces Gelangin flex, a complete analogue of Hexoral. It is available in the form of an aerosol for topical use and is indicated for the treatment of diseases of throat and oral cavity. In 2022, the company produced 2.5 m packages of the drug, and 4.5 m packages are planned for 2023 – 4.5 million packages, the Ministry noted.


Exit mobile version